Kringle Pharma, Inc.
Kringle Pharma, Inc. scores highest on Nitro (64) and lowest on Earnings (4). Its PosiPenta is 31.02 out of 100, weaker than most similar companies.
On the Penta Grid this week, Kringle Pharma, Inc. is Grid #51 of 53 in the Healthcare sector in Japan, and Grid #1,002 of 1,059 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Kringle Pharma, Inc. | 31.02 | 9 | 4 | 64 | 50 | 28 |
| Hi-CRATES CO.,LTD. | 68.48 | 80 | 55 | 65 | 83 | 60 |
| PRISM BioLab Co.,LTD | 23.97 | 13 | 16 | 17 | 53 | 21 |
| AIAI Group Corporation | 49.19 | 82 | 63 | 15 | 46 | 40 |
| Kohjin Bio Co., Ltd. | 34.55 | 54 | 39 | 9 | 36 | 36 |
| Nippon Chemiphar Co., Ltd. | 36.69 | 50 | 13 | 41 | 22 | 58 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -5.14 |
| P/B ratio | 3.64 |
EEarnings
| Trailing EPS | ₹-66.60 |
| Forward EPS | — |
NNitro
| Price | 342.03 |
| 52-week high | 448.58 |
| 52-week low | 173.74 |
| Fall from 52-week high | 23.8% |
TTorque
| Return on equity (ROE) | -61.23% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | 0.38 |
| Market cap | ₹276 Cr |
| Insider holding | 19.31% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Kringle Pharma, Inc.'s PosiPenta score?
Kringle Pharma, Inc.'s PosiPenta is 31.02 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does Kringle Pharma, Inc. stand on the Penta Grid?
On the Penta Grid this week, Kringle Pharma, Inc. is Grid #51 of 53 in the Healthcare sector in Japan, and Grid #1,002 of 1,059 in Japan.
Which PosiPenta pillar is strongest for Kringle Pharma, Inc.?
Nitro (momentum), with a score of 64 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Kringle Pharma, Inc.?
Earnings (growth), with a score of 4 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.